Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into an agency and technology transfer agreement with Egyptian firm Gennvax Egypt concerning Kangtai’s 13-valent pneumococcal polysaccharide conjugate vaccine. Under the terms of the agreement, the two companies will collaborate to advance the marketing approval of the vaccine in Egypt, with plans to partition raw materials within the country.
This strategic partnership signifies a step forward in the global expansion of Kangtai’s vaccine portfolio and aims to enhance vaccine accessibility in Egypt, potentially contributing to public health initiatives in the region.- Flcube.com
